Changing Treatment Paradigms for Myelodysplastic Syndromes in a Community Oncology Practice: Georgia Cancer Specialists' Experience
暂无分享,去创建一个
B. Feinberg | M. Saleh | J. Gilmore | W. Lenz | C. Franco | Tom Gondesen
[1] J. Reeves,et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. , 2008, Blood.
[2] Thomas H Müller,et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.
[3] Sonali M. Smith,et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation , 2007, Bone Marrow Transplantation.
[4] A. Jemal,et al. Cancer mortality in the United States by education level and race. , 2007, Journal of the National Cancer Institute.
[5] A. Raza,et al. Current Treatment Options: Impact of Cytogenetics on the Course of Myelodysplasia , 2007, Current treatment options in oncology.
[6] M. Tomonaga,et al. Retrospective nationwide survey of Japanese patients with transfusion‐dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality , 2007, European journal of haematology.
[7] E. Estey,et al. Acute myeloid leukemia and myelodysplastic syndromes in older patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. Mayne,et al. Myelodysplastic syndromes , 2007, Cancer.
[9] M. L. Thomas. Strategies for achieving transfusion independence in myelodysplastic syndromes. , 2007, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[10] J. Issa,et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome , 2007, Cancer.
[11] C. Schiffer. Myelodysplasia: the good, the fair and the ugly. , 2007, Best practice & research. Clinical haematology.
[12] H. Kantarjian,et al. The role of decitabine in the treatment of myelodysplastic syndromes , 2007, Expert opinion on pharmacotherapy.
[13] J. Issa,et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.
[14] Herschel Knapp,et al. Lay patient navigator program implementation for equal access to cancer care and clinical trials , 2006, Cancer.
[15] T. Cosgriff,et al. Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes. , 2006 .
[16] R. Mertelsmann,et al. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. , 2006, Haematologica.
[17] A. List,et al. Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes. , 2006, Current pharmaceutical biotechnology.
[18] R. Larson,et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[20] M. Lübbert,et al. Superiority of prolonged low‐dose azanucleoside administration? , 2006, Cancer.
[21] John M Bennett,et al. Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.
[22] H. Møller,et al. The incidence and outcome of myeloid malignancies in 2,112 adult patients in South East-England. , 2006 .
[23] C. Bloomfield,et al. Myelodysplastic syndromes clinical practice guidelines in oncology. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.
[24] J. Schulte‐Mönting,et al. Comparison of five prognostic scoring systems, the French–American–British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis , 2006, Annals of Hematology.
[25] J. Bennett. A comparative review of classification systems in myelodysplastic syndromes (MDS). , 2005, Seminars in oncology.
[26] M. Sekeres,et al. Alternative treatments for myelodysplastic syndromes. , 2005, Seminars in hematology.
[27] L. Rimsza,et al. Efficacy of lenalidomide in myelodysplastic syndromes. , 2005, The New England journal of medicine.
[28] Harlan M Krumholz,et al. Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.
[29] L. Balducci. Anemia, cancer, and aging. , 2003, Cancer control : journal of the Moffitt Cancer Center.
[30] M. Christian,et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Kelly,et al. 'More than just money' -- widening the understanding of the costs involved in cancer care. , 2001, Journal of advanced nursing.
[32] I. Jaiyesimi,et al. Myelodysplastic syndrome at a large tertiary care community hospital: analysis according to the international prognostic scoring system. , 2000, Leukemia research.
[33] R. Costabile. Cancer and male sexual dysfunction. , 2000, Oncology.
[34] C. Coltman,et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.
[35] D. Cella,et al. Age and clinical decision making in oncology patients. , 1994, Journal of the National Cancer Institute.
[36] A. Gratwohl,et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG) , 1990, British journal of haematology.